Virax Biolabs Group Ltd
VRAX
Company Profile
Business description
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual’s immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Contact
Bo’Ness Road Newhouse
BioCity Glasgow
LondonML1 5UH
GBRT: +44 2077887414
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2026
Employees
17
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,524.60 | 4.40 | 0.05% |
| CAC 40 | 7,836.79 | 37.04 | -0.47% |
| DAX 40 | 23,527.01 | 111.55 | -0.47% |
| Dow JONES (US) | 42,051.06 | 89.37 | -0.21% |
| FTSE 100 | 8,585.01 | 17.91 | -0.21% |
| HKSE | 23,565.70 | 74.95 | -0.32% |
| NASDAQ | 19,146.81 | 136.72 | 0.72% |
| Nikkei 225 | 37,705.74 | 422.39 | -1.11% |
| NZX 50 Index | 12,825.62 | 46.36 | 0.36% |
| S&P 500 | 5,892.58 | 6.03 | 0.10% |
| S&P/ASX 200 | 8,291.50 | 11.90 | 0.14% |
| SSE Composite Index | 3,388.61 | 15.34 | -0.45% |